TMCI Investors are Urged to Contact Robbins LLP for Information About the Treace Medical Concepts, Inc. Class Action Lawsuit
SAN DIEGO, CA - May 3, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product
According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024.
What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
[email protected]
(800) 350-6003
www.robbinsllp.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Prediction: 1 Artificial Intelligence (AI) Stock to Buy Before It Soars 100% in the Next Year (Hint: Not Palantir)
CoreWeave shares have already tripled since the company held its initial public offering in March 2025. Research company SemiAnalysis recently recognized CoreWeave as the best GPU cloud on the market. CoreWeave's sales rose 420% in the first quarter, and that momentum could help the stock double in the next year. 10 stocks we like better than CoreWeave › Palantir Technologies (NASDAQ: PLTR) has been an incredible investment throughout the artificial intelligence (AI) boom. The stock has advanced 1,900% since January 2023. But CoreWeave (NASDAQ: CRWV) could be the next big winner as the AI boom continues to unfold. The company held its initial public offering two months ago, and the share price has already tripled, but I think CoreWeave stock can double again in the next year. Here's why. CoreWeave provides cloud infrastructure and software services. Its platform (called a GPU cloud) is purpose-built for demanding workloads like artificial intelligence (AI). Research company SemiAnalysis recently ranked CoreWeave as the best GPU cloud on the market, awarding it higher scores than competitors like Amazon, Microsoft, and Alphabet's Google. CoreWeave has distinguished itself from those hyperscalers in two ways. First, it is frequently the first cloud to deploy the latest Nvidia technologies due to its close relationship with the chipmaker. Second, CoreWeave is very good at running GPU clusters, such that it frequently achieves record-breaking results at the MLPerf benchmarks: objective tests that measure the performance of AI systems. CoreWeave reported tremendous first-quarter financial results. Revenue increased 420% to $981 million, and adjusted operating income (which excludes stock-based compensation and interest payments on debt) increased 550% to $162 million. As a caveat, the company reported a non-GAAP (generally accepted accounting principles) net loss of $150 million because interest payments on debt cut into profits. However, significant debt is unavoidable when building AI infrastructure, and CoreWeave has a responsible borrowing strategy involving what management calls "naturally deleveraging self-amortizing debt facilities." That means the company only takes on debt when a customer contract creates a need for additional AI infrastructure, and only if that contract more than covers the cost of the debt. CoreWeave disclosed an impressive customer list when it filed its Form S-1 with the SEC prior to its initial public offering, including IBM, Meta Platforms, Microsoft, and Nvidia. Since then, CoreWeave has won new contracts with OpenAI and an unnamed hyperscaler, such that the company now has a revenue backlog of nearly $26 billion. CoreWeave currently trades at 26 times sales. That is objectively expensive, but it seems reasonable for a company with triple-digit revenue growth and a gross margin of 73%. For instance, fellow cloud services company Cloudflare reported 27% revenue growth with a 77% gross margin in the most recent quarter, and that stock trades at 35 times sales. Here's why I think CoreWeave stock can double during the next year: Wall Street estimates trailing-12-month sales will grow 200% over the next four quarters. If that happens, shares can double while the price-to-sales ratio drops to a more reasonable 17. That seems plausible, provided demand for AI infrastructure remains robust. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Trevor Jennewine has positions in Amazon, Nvidia, and Palantir Technologies. The Motley Fool has positions in and recommends Alphabet, Amazon, Cloudflare, International Business Machines, Meta Platforms, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Prediction: 1 Artificial Intelligence (AI) Stock to Buy Before It Soars 100% in the Next Year (Hint: Not Palantir) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
2 Growth Stocks to Buy and Hold Forever
Amazon's constant innovation is a hallmark of a business that will still be around in 50 years. Netflix is a highly profitable entertainment business that is still finding new avenues of growth. 10 stocks we like better than Amazon › Buying growth stocks that you intend to hold forever is a smart strategy. It forces you to think about companies that will still be around in 50 years. This raises the odds that the stock will keep compounding in value over your lifetime, which is the lazy way to get rich without doing much work. If this sounds like a good plan, here are two stocks to consider buying. Amazon (NASDAQ: AMZN) has profitable revenue streams coming from e-commerce, cloud computing, retail advertising, and third-party fulfillment services. It generated $21 billion in free cash flow on $650 billion of revenue over the last year. The foundation of Amazon's business is its online store, making up 37% of first-quarter revenue. Its wide selection, delivery infrastructure, and large customer base with more than 200 million Prime members give Amazon a strong competitive advantage. Amazon's investments in robotics to automate inventory management and order processing are strengthening its competitive advantage in a $4 trillion global e-commerce market. Amazon continues to push the limits of delivery speeds. In Q1, it set a new record for items delivered the same or next day. It's probably not by accident that this accomplishment follows the unveiling of its next-generation fulfillment center in Shreveport, Louisiana, in 2024. This facility is powered by artificial intelligence (AI) and uses 10 times more robotics than the company's other facilities. Amazon said its new fulfillment center will set a new standard for the retail industry. This is an incredibly innovative company that has progressed from selling out of a garage 30 years ago to using AI to deliver millions of items at blazing speed. That's the kind of business you want to invest in. Amazon's investments in AI bolster its long-term prospects. Analysts currently expect the company's earnings to grow at an annualized rate of 17% in the coming years, which reflects expectations for improving margins in its retail business, in addition to strong growth from other high-margin services like cloud computing and advertising. Amazon has a lot of levers it can pull to create shareholder returns. Netflix (NASDAQ: NFLX) stock continues to hit new highs. It has evolved from a DVD-by-mail rental service 20 years ago to a dominant streaming service. Over the last year, the company generated $7 billion in free cash flow on $40 billion of revenue, and it keeps growing. Its growing cash flow paves the way for increasing content spend to keep winning more subscribers. People have varying entertainment preferences, and Netflix can afford to make a wide variety of content that pleases everyone. It spent $17 billion in content production last year and still reported a stellar 22% profit margin. Netflix still has a huge opportunity internationally. Its growing budget will allow it to invest in widening its content offering to appeal to different cultures. Netflix started investing in local infrastructure to support its growth plans a decade ago and is now producing content in more than 50 countries. What's more, Netflix is testing new content formats to widen the viewership. Its livestream of the Taylor-Serrano fight in November was the most-watched professional women's sports event in U.S. history. With more than 700 million people watching content on its platform, Netflix could also see advertising revenue soar in the coming years. Ad-supported subscriber plans come at a lower price point, helping the company expand its audience reach and boost margins at the same time. Analysts expect its earnings to grow at an annualized rate of 22% over the next several years. Netflix's strong brand and high-margin business have the makings of a stock that is going to reward shareholders for many years. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Netflix. The Motley Fool has a disclosure policy. 2 Growth Stocks to Buy and Hold Forever was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) yesterday and set a price target of $68.00. The company's shares closed yesterday at $47.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Oruka Therapeutics, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -2.8% and a 45.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on June 3. However, on May 30, Bank of America Securities maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). The company has a one-year high of $53.27 and a one-year low of $19.45. Currently, Kymera Therapeutics has an average volume of 856.8K.
